Local Privilege Escalation Risk in Microsoft Defender (CVE-2026-33825)

Historical catalog analysis: CISA added this entry on April 22, 2026. The entry reflects catalog information retrieved on August 31, 2026, not a snapshot archived on the inclusion date. Check current vendor guidance before acting.

What the vulnerability is

CVE-2026-33825 is a security flaw in Microsoft Defender characterized by insufficient granularity of access control (CWE-1220). This vulnerability allows an attacker who already has authorized access to a system to escalate their privileges locally. According to CISA, this specific flaw has been observed in use by ransomware campaigns.

Exposure and applicability

This vulnerability is applicable to healthcare environments utilizing Microsoft Defender as a primary security tool for endpoints, servers, or workstations. Because the flaw enables local privilege escalation, it is particularly relevant for systems that store or process electronic Protected Health Information (ePHI) where strict access controls are required under the HIPAA Security Rule.

While the vulnerability requires an attacker to already have some level of authorized access to the system, the reported use in ransomware campaigns suggests that once initial entry is achieved, this flaw could be used to gain the higher-level permissions necessary to disable security software or deploy encryption payloads across a network.

Remediation priorities

Our analysis suggests that healthcare security leaders prioritize remediation based on the criticality of the asset and its proximity to patient data. We recommend the following prioritized actions:

1. Apply Vendor Updates: The primary defense is to apply mitigations provided by Microsoft. This should be prioritized for systems with direct access to ePHI databases or clinical application servers.
2. Review Local Access Permissions: Since this is a local privilege escalation flaw, auditing who has authorized access to sensitive endpoints could reduce the number of potential starting points for an attacker.
3. Segment High-Risk Assets: For legacy systems or medical devices where immediate patching may be complex, ensuring these assets are isolated from general user networks can limit the ability of an attacker to reach a position where they can exploit local flaws.

How to validate remediation

To verify that exposure has been reduced, security teams should:
* Verify Versioning: Confirm that the installed version of Microsoft Defender matches the patched versions specified in the vendor’s update guide.
* Audit Privilege Logs: Review system logs for unauthorized attempts to elevate privileges or unusual account behavior on critical servers.

Note: A version check confirms a patch was applied but does not guarantee total security against all attack vectors.

Limits and open questions

It remains unclear exactly how the ransomware campaigns mentioned by CISA are achieving initial access before leveraging this local privilege escalation. Furthermore, while CISA has set a remediation deadline of May 6, 2026, for federal agencies, this date is not a legal mandate for private healthcare providers, though it serves as a benchmark for urgency.

Residual risk remains if attackers utilize other undiscovered vulnerabilities to gain initial access or if administrative credentials have already been compromised via other means.

Source and editorial note

CVE-2026-33825: Microsoft Defender Insufficient Granularity of Access Control Vulnerability · Source date: April 22, 2026 · Retrieved August 31, 2026.

Material facts are tied to the cited primary source. Recommendations are independent defensive analysis unless attributed to the source. Confirm consequential decisions against current authoritative guidance.

Archive date: April 25, 2026. The displayed post date is assigned three days after the source date to organize this retrospective archive; it does not mean this site published the analysis then. First published by this site: September 11, 2026 at 01:16 UTC.

Request a healthcare security assessment